Tredje AP fonden Sells 39,465 Shares of Baxter International Inc. (NYSE:BAX)

Tredje AP fonden reduced its position in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,466 shares of the medical instruments supplier's stock after selling 39,465 shares during the period. Tredje AP fonden's holdings in Baxter International were worth $1,151,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Riverview Trust Co boosted its holdings in shares of Baxter International by 5,488.2% during the fourth quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 933 shares during the period. LRI Investments LLC boosted its holdings in shares of Baxter International by 60.8% during the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier's stock worth $59,000 after purchasing an additional 590 shares during the period. Bruce G. Allen Investments LLC boosted its holdings in shares of Baxter International by 247.3% during the fourth quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier's stock worth $76,000 after purchasing an additional 1,867 shares during the period. CKW Financial Group boosted its holdings in shares of Baxter International by 19.3% during the fourth quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier's stock worth $77,000 after purchasing an additional 425 shares during the period. Finally, West Oak Capital LLC boosted its holdings in shares of Baxter International by 345.3% during the fourth quarter. West Oak Capital LLC now owns 3,785 shares of the medical instruments supplier's stock worth $110,000 after purchasing an additional 2,935 shares during the period. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Baxter International Stock Down 1.3 %

Shares of BAX traded down $0.45 on Wednesday, hitting $34.07. 5,109,375 shares of the stock traded hands, compared to its average volume of 4,884,309. The company has a market capitalization of $17.43 billion, a PE ratio of -26.61, a P/E/G ratio of 0.93 and a beta of 0.60. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. The business has a 50 day simple moving average of $32.66 and a 200 day simple moving average of $33.90. Baxter International Inc. has a one year low of $28.33 and a one year high of $43.99.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The company had revenue of $2.75 billion during the quarter, compared to the consensus estimate of $2.67 billion. As a group, equities analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Friday, February 28th will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 2.00%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International's dividend payout ratio (DPR) is presently -53.13%.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Baxter International from $38.00 to $36.00 and set a "neutral" rating for the company in a report on Friday, February 21st. The Goldman Sachs Group assumed coverage on shares of Baxter International in a report on Wednesday, February 26th. They issued a "buy" rating and a $42.00 price objective for the company. Barclays raised their price objective on shares of Baxter International from $39.00 to $41.00 and gave the stock an "overweight" rating in a report on Monday, March 10th. Argus upgraded shares of Baxter International from a "hold" rating to a "buy" rating in a report on Monday, February 24th. Finally, Citigroup lowered their price objective on shares of Baxter International from $37.00 to $35.00 and set a "neutral" rating for the company in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $38.56.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.